VIDEO: Local radiotherapy benefits quality of life, not OS, in certain prostate cancers
CHICAGO — In this Healio video exclusive, Silke Gillessen, MD, discusses a study that confirms the triplet combination in de novo, low-volume, metastatic, castration-sensitive prostate cancer as the best course of action.
Gillessen, medical oncologist for the Oncology Institute of Southern Switzerland, spoke about the research by Alberto Bossi, MD, and colleagues presented at ASCO Annual Meeting. The study presented results from PEACE-1, a phase 3 randomized trial.
Researchers randomized 1,172 patients with de novo, low-volume, metastatic, castration-sensitive prostate cancer to receive either standard of care (SOC) with or without abiraterone acetate (Zytiga, Janssen) plus prednisone (AAP) and prostate radiotherapy (RT) or SOC with or without AAP without RT, according to researchers.
“PEACE-1 showed that radiotherapy has a beneficial effect. ... If you add the local radiotherapy, you have less local complications later. That’s quite important for our patients because it’s important for quality of life,” Gillessen said. “It also improved cancer control, but it didn’t improve overall survival — at least not in the analysis that was shown now. That’s a very important trial in the sense that it confirms what a lot of us are already doing to continue to give the triplet.”
When compared individually to SOC, radiographic PFS improved with SOC, AAP and RT and borderline improved with SOC and AAP. Adding prostate RT to systemic treatment did not improve OS in patients with de novo metastatic, castration-sensitive prostate cancer, according to the study.
“We’re making a lot of progress in this disease, and the PEACE-1 trial has helped us to better understand how to treat our patients and how to individualize their treatment,” Gillessen continued.
Reference:
- Bossi A, et al. Abstract LBA5000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.